Dialysis Devices and Equipment Market Definition

The dialysis devices and equipment market consists of the sale of dialysis devices and equipment and related services by entities (organizations, sole traders and partnerships) that manufacture dialysis devices and equipment which are used in the treatment of dialysis patients. The dialysis devices and equipment industry includes establishments that manufacture dialysis devices and equipment such as dialyzers and dialysis pumping machines and other instruments used in the dialysis process, including blood pumps, catheters and tubing kits. Dialysis devices and equipment are used in the dialysis process to filter the patient’s blood, in order to remove waste products such as urea, creatinine and excess water, such impurities usually occur when the kidneys fail or are damaged. Dialysis allows patients with kidney failure a chance to live productive lives. There are three types of dialysis – hemodialysis dialysis, peritoneal dialysis and continuous renal replacement.

Anemia and Other Blood Disorder Drugs refer to the medications or drugs that are used to treat anemia and other blood disorder diseases. It refers to a blood condition that develops when a medication prompts the body's immune system to begin attacking its own red blood cells. Hemolysis, a process that causes red blood cells to degrade earlier than usual, is brought on by this. The main types of anemia and other blood disorder drugs are iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, and aplastic anemia. Iron deficiency anemia is a common kind of anemia in which the blood does not contain enough healthy red blood cells. The oxygen-carrying red blood cells transport oxygen to the body's cells. The different types of anemia include microcytic (Low MCV), normocytic (Normal MCV), and macrocytic (High MCV) and involve various routes of administration such as oral, and injectable. It is distributed through hospitals pharmacies, online pharmacies, and pharmacy. The anemia and other blood disorder drugs market research report are one of a series of new reports from The Business Research Company that provides anemia and other blood disorder drugs market statistics, including anemia and other blood disorder drugs industry global market size, regional shares, competitors with anemia and other blood disorder drugs market share, detailed anemia and other blood disorder drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anemia and other blood disorder drugs industry. This anemia and other blood disorder drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global anemia and other blood disorder drugs market size will grow from $11.14 billion in 2022 to $11.87 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anemia and other blood disorder drugs market size is expected to grow to $14.80 billion in 2027 at a CAGR of 5.7%. The increasing prevalence of anemia among the global population acts as a strong driving factor for the market. Unhealthy lifestyles, changing dietary habits and increased stress levels increased the cases of anemia worldwide. For instance, anemia was found to be the most frequent disease in the elderly population (> 65 years of age), reaching a prevalence rate of around 17%. the World Bank reported that anemia is the 8th leading cause of disease among women and the young population. Growth in the prevalence rate of anemia drives the market. There has been an increase in the use of biologics for treating anemia and other blood disorders. Biologics are composed of protein, sugar, nucleic acids, or a combination of these substances or might be derived from living organisms like humans, animals, or microorganisms or that may contain components of living organisms. The growth in the use of biologics over the drugs restricts the market resulting in the decline of the number of drugs being used for the treatment of anemia& other blood disorders. For example, Hospira, a medical device and pharmaceutical company, submitted its first biologics license application to FDA for the approval of a drug that treats anemia. Moreover, the FDA approved the first Epoetin Alfa biosimilar for the treatment of anemia caused by chronic kidney disease, chemotherapy, or the use of zidovudine in patients with HIV infection. The increase in the use of biologics will hamper the growth of the market. Companies in the anemia and other blood disorder drugs market are collaborating with other companies to develop and commercialize a specific kind of drug by sharing the knowledge, technology, and cost. Such collaborations are also helpful to the companies in case of expiring licenses and a stringent regulatory environment. For example, in 2020, Akebia Therapeutics announced collaboration with Tobacco Inc. to treat adult patients with iron deficiency anemia. Another such example is, Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. agreed to manufacture and commercialize vadadustat, an oral HIF stabilizer, used for the treatment of anemia. The anemia and other blood disorder drugs market is governed by several regulatory bodies that regulate their functioning by carrying out quality checks for that drug before it can be launched in the market. For instance, the U.S. Food & Drug Administration (FDA) requires every pharmaceutical company to get its drugs examined by the concerned authority. FDA sorts to a Risk Evaluation and Mitigation Strategy (REMS) for determining the safety and quality standards of the drug and grants approvals only if the standards are up to the mark. In October 2022, Pfizer, a US-based pharmaceutical company acquired Global Blood Therapeutics Inc. for an undisclosed amount. Through this acquisition, Pfizer expanded its portfolio in the development of drugs and brought various potential best-in-class treatments to people living with sickle cell disease. Global Blood Therapeutics Inc. is a US-based biotech company operating in anemia and other blood disorder drugs. Major players in the anemia and other blood disorder drugs market are Amgen Inc., GlaxoSmithKline PLC., Akebia Therapeutics, Bayer AG, Pfizer Inc., Regenbiopharma, Hoffmann-La Roche Ltd., Merck Sharp &Dohme Corp., Novartis AG and Janssen Pharmaceutical. North America was the largest region in the anemia and other blood disorder drugs market in 2022. Middle East is expected to be the fastest-growing region in the global anemia and other blood disorder drugs market during the forecast period. The regions covered in the global anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anemia and other blood disorder drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The anemia and other blood disorder drugs market consists of sales of folate analogues, multivitamin and mineral supplements, iron supplements, and erythropoiesis-stimulating agents. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anemia and other blood disorder drugs market is segmented - 1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia 2) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy 3) By Route of Administration: Oral, Injectable 4) By Anemia Type: Microcytic (Low MCV), Normocytic (Normal MCV), Macrocytic (High MCV)

Stem cell/cord blood banking is the process of storing stem cells or blood from the umbilical cord. It is used to treat future injuries. By taking stem cells from the placenta and umbilical cord and preserving them for later use, cord blood banking can possibly save lives. The main cell types of stem cell/cord blood banking are adult stem cells, umbilical cord blood stem cells, and embryonic stem cells. Adult stem cells are a rare population of cells found in the body for the majority of postnatal life that give rise to a limited number of mature cell types that form the tissue in which they dwell. The different types of services include collection, processing, analysis, storage and involves various types of banks such as private banks, and public banks. The different applications include leukemia, anemia, thalassemia, autism, cerebral palsy, diabetes, and others. The stem cell/cord blood banking market research report is one of a series of new reports from The Business Research Company that provides stem cell/cord blood banking market statistics, including stem cell/cord blood banking industry global market size, regional shares, competitors with a stem cell/cord blood banking market share, detailed stem cell/cord blood banking market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell/cord blood banking industry. This stem cell/cord blood banking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global stem cell/cord blood banking market size will grow from $10.23 billion in 2022 to $11.15 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global stem cell/cord blood banking market size is expected to grow to $16.36 billion in 2027 at a CAGR of 10.1%. Increasing number of cancer patients is a major driver for the stem cell /cord blood banking market. Cancer diseases such as leukemia and multiple myeloma can be treated by stem cell transplant. In stem cell transplant, treatment can be either done by autologous transplant in which the stem cells come from the same person who gets the transplant or by allogeneic transplant in which means the stem cells come from a matched related or unrelated donor. By using stem cells in the treatment of cancer, the blood forming stem cells which are damaged during chemotherapy can be restored. According to a report by WebMD,an American publisher of health related news, in 2021, 10 million people died of cancer worldwide. which can be treated by transplanting the stem cells. Lack of awareness especially among pregnant women is a major restraint for the stem cell/cord blood banking market. This is mainly because a majority of pregnant women are unaware of the functioning of the public cord blood banks. Hence, this option is not fully explored despite the advantages of stem cell transplantation in treating cancer. For example, according to the survey by International Journal of Reproduction, Contraception, Obstetrics and Gynecology (IJRCOG), only 45% of pregnant women were informed about the uses of umbilical cord blood during pregnancy, just 5% were aware about the cost of the procedure and less than 1% were aware about the availability of cord blood banking. Pairing of cord blood and tissue storage with genetic testing services is an emerging trend in the stem cell/cord blood banking market. Such pairing is possible and efficient because of its complimentary services to the existing clients, thereby helping in expanding their product portfolio. For example, genetic testing company Natera launched the Evercord cord blood and tissue storage service that enables expectant parents to collect, store and potentially retrieve their newborn's cord blood and tissue for therapeutic use in transplantation and regenerative medicine applications. The US Food and Drug Administration (FDA) outlines guidance related to stem cells/cord blood banking in accordance with section 212 of the Small Business Regulatory Enforcement Fairness Act (Public Law 104-121). As per this act, stem cells sourced from cord blood for unrelated allogeneic use are regulated by the FDA, and, in order to distribute these products, distributors need to get a license from the FDA. These licenses are provided by the FDA after reviewing the manufacturing and the storage conditions. In this regard, the American Association of Blood Banks (AABB) and other regulatory agencies also work with the FDA. Hence, the regulatory scenario related to the stem cells/cord blood banking market is expected to keep a check on companies involved in this market. In December 2021, Cooper Companies, a U.S.-based medical device company, acquired Generate Life Sciences for $1.66 billion. The acquisition would enable Cooper & Co. to better serve their consumers and expand their customer base. Generate Life Sciences is a US-based provider of donor eggs and sperm for fertility treatments, fertility cryopreservation services, and newborn stem cell storage (cord blood and cord tissue) services.  Major players in the stem cell/cord blood banking market are AMAG Pharmaceuticals, Cordlife, Cryo-Cell International, Esperite, Americord Registry LLC., China Cord Blood Corporation, Cordlife Group Limited, CordVida, ESPERITE N.V., and Cryo Stemcell. North America was the largest region in the stem cell/cord blood banking market in 2022. Western Europe was the second largest region in the global stem cell/cord blood banking market. The regions covered in the global stem cell/cord blood banking market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the stem cell/cord blood banking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The stem cell/cord blood banking global market includes revenues earned by entities by providing services such as cryopreservation and collection services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global stem cell/cord blood banking market is segmented - 1) By Cell Type: Adult Stem Cells, Umbilical Cord Blood Stem Cells, Embryonic Stem Cells 2) By Service: Collection, Processing, Analysis, Storage 3) By Bank Type: Public, Private 4) By Application: Leukemia, Anemia, Thalassemia, Autism, Cerebral Palsy, Diabetes, Other Applications

Haematology analyzers provide complete blood count (CBC) with a three-part differential white blood cell (WBC) count and can detect small cell populations to diagnose rare blood conditions, measure cell morphology. The main products in haematology analyzers and reagents are haematology analyzers, hemostasis analyzers, plasma protein analyzers, haemoglobin analyzers, erythrocyte sedimentation rate analyzers, coagulation analyser, flow cytometers, slide stainers, differential counters, and haematology stains. The hematology analysers are devices that measure the concentration of haemoglobin in a blood sample. The various applications include anemias, blood cancers, hemorrhagic conditions, infection-related conditions, immune system-related conditions, and others that are used by end-users such as specialised research institutes, hospitals, specialised diagnostic centres, and others. The haematology analyzers and reagents market research report is one of a series of new reports from The Business Research Company that provides haematology analyzers and reagents market statistics, including haematology analyzers and reagents industry global market size, regional shares, competitors with a haematology analyzers and reagents market share, detailed haematology analyzers and reagents market segments, market trends and opportunities, and any further data you may need to thrive in the haematology analyzers and reagents industry. This haematology analyzers and reagents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hematology analyzers and reagents market grew from $4.14 billion in 2022 to $4.56 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hematology analyzers and reagents market is expected to grow from $5.67 billion in 2027 at a CAGR of 5.6%. The rising number of blood donations globally is driving the hematology analyzers and reagents market as hematology analyzers are used to test and screen blood in blood banks. Blood collected from donors through blood donation camps or bloodmobiles is sent to blood banks where hematology analyzers are used to screen and test the blood. These screening tests determine the blood type, analyze the blood plasma and detect infectious diseases. Blood banks are witnessing a huge outflow of blood to hospitals and other end-users and an inflow of blood from blood donations daily. According to the WHO, there was an increase of 7.8 million blood donations from voluntary unpaid donors. As the number of people donating blood increases, the demand for hematology analyzers and reagents increases, thereby driving the market growth. Recalls of defective hematology analyzers are acting as a restraint on the hematology analyzers and reagents market. A product recall is done by the manufacturer or developer of the product as a precautionary measure when safety issues or defects are discovered that can endanger the consumer. A faulty hematology analyzer may provide wrong results and may lead to misdiagnosis, affecting consumer confidence in the analyzers. Regulatory authorities caution healthcare professionals to be aware of the potential for inaccurate diagnostic results with these analyzers and to take appropriate actions including the use of alternative diagnostic testing or confirming analyzer results with manual scanning or estimate of cell counts. For instance, Beckman Coulter Life Sciences recalled its DxH800 and DxH600, and DxH 900 hematology analyzers due to the risk of inaccurate results. Such kind product recalls not only pose a serious safety risk to the public but can also cause significant financial and reputational damage to the companies concerned. Hematology analyzers manufacturers are increasingly investing in the research and development of analyzers with microfluidics technology that use low volumes of samples and reagents. Microfluidics deal with the flow of liquids inside channels as small as a few micrometers. Low reagent consumption by hematology analyzers with microfluidics technology helps reduce operating costs significantly. For instance, the HA5 hematology system from BioSystems is based on microfluidics technology and uses approximately 75% fewer reagents compared to normal hematology analyzers. Also, the respons®3H and respons®5H hematology systems by DiaSys use microfluidics technology and consume 70% fewer reagents. In May 2021, Soulbrain, a South Korean chemicals company, acquired PixCell Medical for an undisclosed amount. The acquisition would support Soulbrain’s growth strategy in the fields of diagnostics and point-of-care testing. PixCell is an Israeli maker of blood test analyzers. Major players in the haematology analyzers market are Abbott, Bio-Rad Laboratories, Horiba, Siemens, Sysmex, BioSystems, Boule, Danaher, Diatron, and Drew Scientific. North America was the largest region in the haematology analyzers market in 2022. Western Europe was the second largest region in the global haematology analyzers market report. The regions covered in the global haematology analyzers and reagents report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the haematology analyzers market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The haematology analyzers market consists of sales electrolyte analyzer, hemocoagulometer, enzyme standard instrument, blood gas analyzer and immunoturbidimeter. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global haematology analyzers and reagents market is segmented - 1) By Product: Hematology Analysers, Hemostasis Analysers, Plasma Protein Analysers, Hemoglobin Analysers, Erythrocyte Sedimentation Rate Analyser, Coagulation Analyser, Flow Cytometers, Slide Stainers, Differential Counters, Hematology Stains 2) By Applications: Anemias, Blood Cancers, Hemorrhagic Conditions, Infection Related Conditions, Immune System Related Conditions, Other Applications 3) By End User: Specialized Research Institutes, Hospitals, Specialized Diagnostic Centers, Other End Users

Peripheral vascular devices and equipment are used to treat peripheral vascular diseases which are slow and progressive blood circulation disorders caused by blockages, narrowing, or spasms in blood vessels outside the heart and brain including arteries and veins. The main types of peripheral vascular devices and equipment are peripheral vascular stents, percutaneous transluminal angioplasty balloons, catheters, PTA guide wires, atherectomy devices, chronic total Occlusion devices, aortic stents, synthetic surgical grafts, embolic protection devices, and inferior vena cava filters. The catheter is a tubular medical device for insertion into canals, vessels, passageways, or body cavities to permit injection or withdrawal of fluids or to keep a passage open. The applications involved are the treatment of peripheral blood vessels damaged and the treatment of peripheral blood vessels blockage. The various end-users are hospital applications and clinic applications. The peripheral vascular devices and equipment market research report is one of a series of new reports from The Business Research Company that provides peripheral vascular devices and equipment market statistics, including peripheral vascular devices and equipment industry global market size, regional shares, competitors with a peripheral vascular devices and equipment market share, detailed peripheral vascular devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the peripheral vascular devices and equipment industry. This peripheral vascular devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global peripheral vascular devices and equipment market size will grow from $7.77 billion in 2022 to $8.27 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The peripheral vascular devices and equipment market size is expected to grow to $10.04 billion in 2027 at a CAGR of 5.0%. The peripheral vascular devices and equipment market is driven by the rising number of people with peripheral artery diseases. Peripheral artery diseases are caused when arteries in the human body are blocked by plaque consisting of fats, cholesterol, and other substances restricting their blood flow to important organs. Lower extremity peripheral artery disease (PAD) affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes (other cardiovascular diseases such as coronary heart disease and stroke and leg outcomes such as amputation. The disease is different in younger populations; but, the incidence rises sharply, with over 20% of people over 80 years old having PAD. According to the Center for Disease Control and Prevention (CDC), approximately 8.5 million people in the USA are suffering from peripheral artery diseases, of which 12-20% are aged above 60 years. Stringent approval processes, product recalls and failures act as a restraint to the peripheral vascular devices and equipment market. Product recalls and failures potentially affect the brand image of the companies within this market. According to the US Food and Drug Administration (FDA), a product recall is made to perform corrective actions or prevent hazardous effects to patients. For instance, in January 2022, Medtronic was instructed to recall its artery-clearing HawkOne System due to reported injuries. \ To reduce incidences associated with the peripheral devices and ensure that the devices are safe and have the least adverse reactions, FDA is restricting devices for use, sending field safety notices, and making product recall to correct the devices. These stringent approval processes and regulatory policies may impact the peripheral devices and equipment market. Bio-absorbable stents are gaining popularity in the peripheral vascular devices and equipment market to eliminate thrombogenic risk factors and enhance clinical applicability. Bio-absorbable stents are made of natural soluble materials that disappear after insertion and eliminate the risk of late stent thrombosis. They help in protecting the body from inflammation or reduced blood flow due to late-stent thrombosis (a condition where the stent used for treatment stays inside the body for a prolonged period). Companies in this market are increasing their focus on developing and commercializing bio-absorbable stents. For instance, in 2020, Boston Scientific is demanded to start its Synergy Megatron bioabsorbable polymer coronary stent system. It is intended for large proximal vessels, including over main, bifurcations, and ostial lesions. It is made in 3.5 mm to 5.0 mm diameters. It owns enhanced strength and the capacity to create tapered vessels. In January 2022, the U.S Food and Drug Administration issued notice to Medtronic plc for Class I medical device recall for its HawkOne System for clearing out clogged arteries. The notice was issue after certain instances of injuries were reported. In September 2021, Boston Scientific, a US-based manufacturer of medical devices acquired Devoro Medical, Inc for an undisclosed amount. This acquisition of devoro medical inc will add the WOLF platform and advances efforts to ensure physicians have the right tools to improve procedural efficiencies. Devoro Medical, Inc., is a US-based manufacturer of medical technology. Major players in the peripheral vascular devices and equipment market are Medtronic, Boston Scientific Corporation, Abbott, Cook group, Angiomed GmbH & Co., Medizintechnik KG, Terumo Corporation, ENDOLOGIX Inc., Bolton medical Inc., and JOTEC. North America was the largest region in global peripheral vascular devices and equipment market in 2022. Western Europe was the second-largest region in global peripheral vascular devices and equipment market. The regions covered in the peripheral vascular devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the peripheral vascular devices and equipment market are Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, and Australia. The peripheral vascular devices and equipment market consist of sales of peripheral vascular stents, percutaneous transluminal angioplasty balloons, PTA drug-eluting balloons, embolic protection devices, inferior vena cava filters, Aortic stent-grafts, synthetic surgical drafts, and peripheral guide wires. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global peripheral vascular devices and equipment market is segmented - 1) By Type: Peripheral vascular stents, Percutaneous transluminal angioplasty balloons, Catheters, PTA guide wires, Atherectomy devices, Chronic total acclusion devices, Aortic stents, Synthetic surgical grafts, Embolic protection devices, Inferior vena cava filters 2) By End User: Hospital applications, Clinic applications, 3) By Application: Treatment of Peripheral Blood Vessels Damaged, Treatment of Peripheral Blood Vessels Blockage

Blood transfusion diagnostics are used to conduct tests before the transfusion of blood from donor-recipient such as blood grouping disease screening. The main types of blood transfusion diagnostics are instruments and kits, reagents, and others. The blood transfusion diagnostic kits are used to collect and transfuse blood. The technologies involved in blood transfusion diagnostics are western blot, ELISA, nucleic acid amplification, fluorescence assay, and rapid test that are used for various applications such as blood grouping and disease screening. The end-users involved are hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies. The blood transfusion diagnostics market research report is one of a series of new reports from The Business Research Company that provides blood transfusion diagnostics market statistics, including blood transfusion diagnostics industry global market size, regional shares, competitors with a blood transfusion diagnostics market share, detailed blood transfusion diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the blood transfusion diagnostics industry. This blood transfusion diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood transfusion diagnostics market grew from $3.65 billion in 2022 to $3.98 billion in 2023 at a compound annual growth rate (CAGR) of 9.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The blood transfusion diagnostics market is expected to grow from $5.68 billion in 2027 at a CAGR of 9.3%. Patients undergoing surgical procedures need a blood transfusion to replace the lost blood during the procedure. Blood transfusion diagnostics are used during the procedures to screen the blood before transferring it to the patient and will otherwise increase the incidence of infectious disease. According to an article published in the US National Library of Medicine, National Institutes of Health, approximately 310 million surgeries are being performed each year. This increase in the number of procedures will thereby drive the need for blood transfusion diagnostics. Developing and underdeveloped countries lack adequate blood banks, proper medical equipment for blood transfusion, adequate conditions for the storage of blood, and low supply for the high demand of blood. Hospitals are not equipped with proper amenities that help provide hygienic and safe transfusions. For example, according to research conducted by India Spend, around 1.18 million units of blood were wasted during storage in the form of discoloration, bacterial contamination, and expiry due to outdating. The poor infrastructure hampers the growth of the blood transfusion diagnostic market. The growing demand for advanced diagnostic measures and growing prevalence of infectious diseases associated with pathogens such as bacteria & viruses increase the preference for nucleic acid amplification testing (NAAT/NAT) to increase blood safety, improve efficiency and reduce the turnaround time of the results. NAT is a technique that helps detect a particular nucleic acid, virus, or bacteria that acts as a pathogen in blood, tissue, or urine. NAT is highly sensitive and specific for viral nucleic acids and amplifies the region of targeted viral DNA and detects them earlier than the other traditional methods and narrows the period of infectious diseases. For example, XCRP Diagnostic Inc. and Luminex Corporations entered into a licensing agreement of XCR Diagnostic's Xtreme Chain Reaction Nucleic Acid Amplification Technology. In this deal, Luminex got the exclusive rights to use the XCR Diagnostic's NAAT technology for their future molecular diagnostic portfolio. The blood transfusion diagnostics market is highly regulated by governing bodies such as USFDA (the USA Food and Drug Administration), and the Medicines and Healthcare products Agency (MHRA). For instance, the manufacturers and service providers in the USA must comply with the Center for Biologics Evaluation and Research (CBER) Regulations that have been published in the first chapter title 21 of the Code of Federal Regulations (CFR). Part 600 of CFR 21 primarily focuses on the established standards like retention samples conditions, temperature to be maintained during shipment, sterilization of equipment, and role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. Major players in the blood transfusion diagnostics market are BAG Health Care GmbH, Grifols, Bio-Rad Laboratories Inc., Abbott Laboratories, Immucor Inc., Ortho Clinical Diagnostics, DiaSorin S.p.A, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc., and Beckman Coulter Inc. North America was the largest region in the blood transfusion diagnostics market in 2022. Western Europe was the second largest region in the global blood transfusion diagnostics market. The regions covered in global blood transfusion diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the blood transfusion diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The blood transfusion diagnostics market consists of revenues earned by entities by providing installation and maintenance services. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood transfusion diagnostics market also includes sales of blood transfusion diagnostics devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood transfusion diagnostics market is segmented - 1) By Type: Instruments and Kits, Reagents, Other Types 2) By End User: Hospitals, Diagnostic Laboratories, Blood Banks, Plasma Fractionation Companies 3) By Technology: Western Blot, ELISA, Nucleic Acid Amplification, Fluorescence assay, Rapid Test 4) By Application: Blood Grouping, Disease Screening

Blood glucose meters are devices that are used to measure and display the amount of sugar (glucose) in the blood. The main product types of blood glucose meters market are electrode type blood glucose meter and the photoelectric blood glucose meter. Electrode type blood glucose meters are devices that contain electrodes to measure the current generated by an enzymatic reaction between glucose, an enzyme, and a mediator. The various applications included are type 1 diabetes, type 2 diabetes, and gestational diabetes, which are used by various end-users such as hospitals and home care. The blood glucose meters market research report is one of a series of new reports from The Business Research Company that provides blood glucose meters market statistics, including blood glucose meters industry global market size, regional shares, competitors with a blood glucose meters market share, detailed blood glucose meters market segments, market trends and opportunities, and any further data you may need to thrive in the blood glucose meters industry. This blood glucose meters market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global blood glucose meters market size will grow from $15.64 billion in 2022 to $16.96 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The blood glucose meters market size is expected to grow to $22.34 billion in 2027 at a CAGR of 7.1%. The rising prevalence of diabetes is driving the blood glucose meters market. The changing lifestyle, increase in alcohol consumption, physical inactivity, and unhealthy eating habits are leading to an increase in obesity across the globe. Such exponential growth in obese people is causing a stern increase in the purchase of blood glucose meters. Due to obesity, fat tissues release more fat molecules into the blood affecting insulin-responsive cells, which results in reduced insulin sensitivity, in turn, causing diabetes. According to the study by the International Diabetes Federation (IDF), there will be a 48% increase in diabetes around the world by 2045. According to the International Diabetes Federation (IDF) in 2021, nearly 537 million people were suffering from diabetes. The blood glucose meters market growth is restricted due to a lack of awareness of diabetes. Hypo unawareness is a common term used to describe people who have diabetes, especially type 1 diabetes, it is very difficult to notice when they have low blood glucose, hypoglycemia. Such lack of awareness of diabetes and its effects reduces the regular monitoring or check-ups relating to diabetes. For example, in 2021, 537 million adults had diabetes, but more than 1 in 4 did not know that they had the disease. Also, in 2021, According to the International Diabetes Federation (IDF), over one in two (54%) patients with diabetes do not recognize that they have diabetes. The launch of new products is a key trend gaining popularity in the blood glucose meters market. Companies in the market are focusing on the launch of new products to improve their product portfolio and strengthen their market position. For example, in January 2022, Roche, a Swiss multinational healthcare company, launched its new point-of-care blood glucose monitor designed for hospital professionals, with a companion device shaped like a touchscreen smartphone that will run its own apps. Glytec, a US based insulin management software company supplied software for the device, its Glucommander insulin-dosing program to help streamline the complex task of managing blood sugar levels during a patient's hospital stay. FDA regulates blood glucose meters. FDA has released its guidance for the accuracy of blood glucose meters. For blood glucose meters used in the home by patients with diabetes, FDA states that 95% of the measured blood glucose levels should be within 15% of the lab tested value and 99% of the measured values should be within 20% of the lab tested value. For the point of care blood glucose monitoring devices, 95% of the monitored values must be within the range of 12% for blood sugars more than 75mg/dl and must be within 12mg/dl for blood sugars less than 75mg/dl. Also, 98% of the meter values must be within 15% of the range for blood sugars more than 75mg/dl and must be within 15mg/dl for blood sugars less than 75mg/dl. In September 2021, B. Braun Melsungen AG, a German medical and pharmaceutical device company acquired Sterinova Inc for an undisclosed amount. This acquisition of Sterinova will continue to operate as a distinct subsidiary of B. Braun Melsungen AG. Sterinova Inc is a Canada-based company that develops, manufactures, and distributes ready-to-use sterile injectable products in syringes and premix bags. Major players in the blood glucose meters market are Abbott, Roche, Medtronics, Ascensia, Dexcom, Johnson & Johnson, Arkray, Acon, LifeScan, and Agamatrix Inc. North America was the largest region in the global blood glucose meters market in 2022. Western Europe was the second-largest region in the blood glucose meters market. The regions covered in the global blood glucose meters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries in the blood glucose meters market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The blood glucose meters consist of sales of electrode-type blood glucose meter and photoelectric blood glucose meter. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global blood glucose meters market is segmented - 1) By Product type: Electrode Type Blood Glucose Meter, Photoelectric Blood Glucose Meter 2) By End User: Hospitals, Home Care 3) By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes

The hematology drugs market consists of sales of hematology drugs and related services by entities (organizations, sole traders and partnerships) that produce hematology drugs to treat diseases such as genetic disorders, anemia, and other related diseases. This industry includes establishments that produce blood products such as red blood cells, white blood cells, platelets, and fresh frozen plasma. It also consists of establishments which produce of anemia and other blood disorder drugs to treat anemia, hemophilia and blood clots. The main types of hermatology drugs are blood products, anemia and other blood disorder drugs. Any therapeutic substance derived from human blood is referred to as a blood product, which includes whole blood and other blood components for transfusion as well as plasma-derived medicinal products. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global hematology drugs market size is expected to grow from $33.06 billion in 2021 to $36.13 billion in 2022 at a compound annual growth rate (CAGR) of 9.3%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The hematology drugs market is expected to reach $73.67 billion in 2026 at a CAGR of 19.5%. The hematology drugs market growth is aided by stable economic growth forecasted in many developed and developing countries. The International Monetary Fund (IMF) stated that the global GDP growth rate was 3.3% in 2020 and 3.4% in 2021. Recovering commodity prices, after a significant decline in the historic period is further expected to aid the market growth. Developed economies are also expected to register stable growth during the forecast period. Additionally, emerging markets are expected to continue to grow slightly faster than the developed markets in the forecast period. This is expected to increase spending on healthcare services, thereby driving the demand for hematology drugs. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the hematology drugs industry in the historic period. Tranexamic acid is increasingly being used to prevent postpartum hemorrhage (blood loss of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its low price and wide availability. Tranexamic acid is an antifibrinolytic drug that helps in reducing bleeding in surgical and trauma patients, including women with postpartum hemorrhage. According to the World Maternal Antifibrinolytic (WOMAN) trial, using tranexamic acid within three hours of childbirth lowered death from bleeding by 31% and reduced the need for laparotomy (emergency bleeding control surgery) by 36%. The trial included over 20,000 women from 193 hospitals in 21 countries. Major companies in the hematology market include Amgen, Alexion Pharmaceuticals, Bayer AG, F. Hoffmann-La Roche Ltd., CSL, Takeda Pharmaceuticals, Novo Nordisk, Sanofi S.A, Daiichi Sankyo Company and Pfizer Inc. North America was the largest region in the hematology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the hematology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hematology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global hematology drugs market is segmented - 1) By Type: Blood Products, Anemia and Other Blood Disorder Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs